Lv7
4700 积分 2023-02-18 加入
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
9天前
已完结
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
4个月前
已完结
Tirzepatide for Obesity Treatment and Diabetes Prevention
4个月前
已完结
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
4个月前
已完结
Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes
4个月前
已完结
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
4个月前
已完结
Micronutrient and Nutritional Deficiencies Associated With GLP ‐1 Receptor Agonist Therapy: A Narrative Review
5个月前
已完结
GLP‐1 Receptor Agonist Medications for Obesity and Type 2 Diabetes Treatment: A Rapid Review of Changes in Eating Behaviors and Eating Disorder Risk
5个月前
已完结
GLP-1-based therapies for diabetes, obesity and beyond
5个月前
已完结
Assessment of Adverse Events of Teplizumab: A Real-world Pharmacovigilance Study Based on the FDA Adverse Event Reporting System
8个月前
已完结
皖公网安备34019202002308
